CriticalSystemic antimycotics. Imidazole derivatives×Highly selective α1A-adrenergic blocker
Updated · Methodology
Mechanism
The liver clears silodosin mainly through the enzymes CYP3A4, alcohol dehydrogenase and UGT2B7, and P-glycoprotein (P-gp) transports it. Substances that inhibit these enzymes and transporters, ketoconazole among them, can change the levels of silodosin and its active metabolite (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). Ketoconazole strongly inhibits CYP3A4 and can inhibit P-gp (ketoconazole SmPC, EMA). In an interaction study, ketoconazole 400 mg raised peak silodosin concentration 3.7-fold and the area under the curve (AUC) 3.1-fold (silodosin SmPC, EMA). The US label gives 3.8-fold and 3.2-fold (silodosin label, US Food and Drug Administration, FDA). The interaction is likely to be stronger at higher ketoconazole doses and shorter dosing intervals. In Cushing's syndrome, the daily ketoconazole dose reaches 1200 mg (ketoconazole SmPC, EMA).
Symptoms
The higher the silodosin level, the more likely postural hypotension becomes. Postural hypotension was the dose-limiting reaction in healthy men who took up to 48 mg of silodosin a day (silodosin summary of product characteristics, SmPC, European Medicines Agency, EMA). It shows as dizziness on standing and, rarely, fainting (silodosin SmPC, EMA). The most common adverse effects of silodosin are ejaculation disorders: retrograde ejaculation and reduced or absent ejaculate (silodosin SmPC, EMA).
Management
The US silodosin label contraindicates the combination. It names ketoconazole among the strong CYP3A4 inhibitors that silodosin must not be taken with, and the interaction study used ketoconazole (silodosin label, US Food and Drug Administration, FDA). The European silodosin summary of product characteristics (SmPC) is softer but also advises against the pair: it does not recommend silodosin with strong CYP3A4 inhibitors, including ketoconazole (silodosin SmPC, European Medicines Agency, EMA). The ketoconazole documents do not name silodosin. Before starting ketoconazole, review all the patient's medicines. For each one, read its prescribing information on use with a strong CYP3A4 inhibitor (ketoconazole SmPC, EMA, and FDA label). At the first signs of postural hypotension, such as dizziness on standing, ask the patient to sit or lie down until the symptoms pass (silodosin SmPC, EMA). When starting silodosin, warn the patient about driving and operating machinery (silodosin FDA label). The contraindication applies to oral ketoconazole: in the European Union, ketoconazole tablets are used for endogenous Cushing's syndrome (ketoconazole SmPC, EMA). In adults, plasma ketoconazole was undetectable after the cream on the skin or the gel on the scalp, but measurable after the gel on the whole body. No interaction studies have been done with the cream or the gel (ketoconazole cream and gel SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Ketoconazole Tablets USP 200 mg prescribing information (2026)– FDA label, DailyMed setid 1d598696-c6f3-4b7c-ad73-949d2089df35, revised 08/2026, Contraindications
- EMA: Ficha técnica: Ketoconazol (EU/1/14/965), sección 4.3 (2025)– EMA, Ketoconazole Esteve 200 mg comprimidos (autorización europea por procedimiento centralizado), EU/1/14/965/001, ficha técnica (anexo I), información del producto actualizada el 05.05.2025, secciones 4.1, 4.2, 4.3, 4.4 y 4.5
- FDA: Silodosin capsules (silodosin) prescribing information (2026)– FDA, DailyMed setid ee8d577e-948d-4164-9671-c876544ac83b (Novadoz Pharmaceuticals, MSN Laboratories), versión 3, revisión 06/2026, secciones 4, 5.1, 5.4, 7.1 y 12.2; la sección 4 coincide con la de RAPAFLO (setid 96425d91-cfe1-477d-a130-b58c330ca8a3, 02/2012)
- EMA: Ficha técnica: Silodosina – Urorec (EU/1/09/608), sección 4.5 (2026)– EMA, Urorec 8 mg cápsulas duras (Recordati, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 09608011, consultada 16.10.2026, sin fecha de revisión en CIMA, secciones 4.4, 4.5, 4.8 y 4.9
- AEMPS: Ficha técnica: Fungarest 20 mg/g crema (ketoconazol) (nº registro 57595), sección 5.2 (2023)– AEMPS, CIMA, nº registro 57595 (Fungarest 20 mg/g crema, Stada), documento 04/2023 (texto revisado 06/2021), secciones 4.5 y 5.2 (sin concentraciones plasmáticas cuantificables tras uso en la piel de adultos)
- AEMPS: Ficha técnica: Ketoconazol Sandoz 20 mg/g gel (nº registro 66037), sección 5.2 (2023)– AEMPS, CIMA, nº registro 66037 (Sandoz), documento 11/2023 (texto revisado 12/2021), secciones 4.5 y 5.2 (niveles plasmáticos detectados tras aplicación en todo el cuerpo)